

中心：\_\_\_\_\_

姓名：\_\_\_\_\_

### 1150622 社會人士中翻英短文翻譯題目

在剛果民主共和國(Democratic Republic of Congo)，所有受伊波拉病毒(Ebola)所苦的病患已可取得兩種新的實驗療法。研究人員在八月十二日透過一份新聞稿宣布了稱為 REGN-EB3 和 mAb-114 的兩種新療法，它們一直都是試驗的一部分，但由於效果非常好，以致於試驗提前結束。在試驗期間，新療法讓最近患上該病的人存活率提高至百分之八十九至九十四之間。這是重大的進步，因為此病毒今年在剛果截至八月六日止已使兩千七百八十一名受感染者中的一千八百六十六人死亡。

受...所苦 suffer from      實驗療法 experimental treatment

新聞稿 press release      試驗 trial      患上 contract

存活率 survival rates      感染 infect



中心：\_\_\_\_\_

姓名：\_\_\_\_\_

### 1150622 社會人士中翻英短文翻譯參考答案

Two new experimental treatments were made available to all patients suffering from Ebola in the Democratic Republic of Congo. Researchers announced via an August 12th press release that the two treatments, known as REGN-EB3 and mAb114, had been part of a trial but were so effective that the trial was stopped early. During the trial, the new treatments increased survival rates for people who recently contracted the disease to between 89 and 94 percent. This is a major improvement for a virus that, as of August 6, has killed 1,866 of 2,781 infected people in the Congo this year.